Gadolinium-based contrast agent during pelvic MRI: Contribution to patient management in rectal cancer Journal Article
| Authors: | Corines, M. J.; Nougaret, S.; Weiser, M. R.; Khan, M.; Gollub, M. J. |
| Article Title: | Gadolinium-based contrast agent during pelvic MRI: Contribution to patient management in rectal cancer |
| Abstract: | CONCLUSIONS: The use of gadolinium at baseline MRI could have altered treatment in 24% of patients because of differences in tumor stage or position. Postneoadjuvant treatment, gadolinium resulted in statistically smaller distances to sphincters, which could influence surgical decision for sphincter-preserving rectal resection. See Video Abstract at http://links.lww.com/DCR/A444. BACKGROUND: Few publications exist regarding gadolinium-enhanced sequences in rectal MRI. None have evaluated its potential impact on patient management. OBJECTIVE: This study aimed to assess whether gadolinium-enhanced sequences, including dynamic contrast enhancement, change radiologic interpretation and clinical management of rectal cancer. DESIGN: This is a retrospective analysis of 100 rectal MRIs (50 baseline and 50 postneoadjuvant treatment), both without and with gadolinium-enhanced sequences. Treatment plans were rendered based on each radiologic interpretation for each case by a single experienced surgeon. Differences in radiologic interpretation and management were statistically analyzed. SETTINGS: The study was conducted at the Memorial Sloan Kettering Cancer Center. PATIENTS: Patients undergoing rectal MRI between 2011 and 2015 for baseline tumor staging and/or postneoadjuvant restaging were included. MAIN OUTCOME MEASURES: Primary outcome measures were changes in radiologic tumor stage, tumor margins, and surgical planning with the use of gadolinium at baseline and postneoadjuvant time points. RESULTS: At baseline, tumor downstaging occurred in 8 (16%) of 50 and upstaging in 4 (8%) of 50 with gadolinium. Postneoadjuvant treatment, upstaging occurred in 1 (2%) of 50 from T2 to T3a. At baseline, mean distances from tumor to anorectal ring, anal verge, and mesorectal fascia were not statistically different with gadolinium. However, in 7 patients, differences could have resulted in treatment changes, accounted for by changes in relationships to anterior peritoneal reflection (n = 4), anorectal ring (n = 2), or anal verge (n = 1). Postneoadjuvant treatment, distances to anorectal ring and anal verge (in centimeters) were statistically smaller with gadolinium (p = 0.0017 and p = 0.0151) but could not have resulted in clinically significant treatment changes. LIMITATIONS: This study was limited by its retrospective design. |
| Keywords: | adult; aged; aged, 80 and over; middle aged; retrospective studies; neoadjuvant therapy; gadolinium; cancer staging; nuclear magnetic resonance imaging; outcome assessment; magnetic resonance imaging; neoplasm staging; pelvis; metabolism; pathology; diagnostic imaging; retrospective study; outcome assessment (health care); rectal neoplasms; rectum tumor; chemoradiotherapy; rectum; anal canal; surgical margin; procedures; very elderly; humans; human; margins of excision |
| Journal Title: | Diseases of the Colon and Rectum |
| Volume: | 61 |
| Issue: | 2 |
| ISSN: | 0012-3706 |
| Publisher: | Lippincott Williams & Wilkins |
| Date Published: | 2018-02-01 |
| Start Page: | 193 |
| End Page: | 201 |
| Language: | English |
| DOI: | 10.1097/dcr.0000000000000925 |
| PUBMED: | 29337774 |
| PROVIDER: | scopus |
| PMCID: | PMC5772900 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 1 June 2018 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work